Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS-B phase 3 trial of vutrisiran in transthyretin amyloidosis with cardiomyopathy
MOH_2020-04-21_008870Phase 3Not yet recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Feb 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) comparing Vutrisiran with Placebo (2 arms). Primary endpoint: All-cause mortality and cardiovascular hospitalizations. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
vutrisiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on MOH_2020-04-21_008870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-04-21_008870.